A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B
subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28
Days treatment with EDP-514.